ORPOF - OSE Immunotherapeutics SA GAAP EPS of -Euro0.11 revenue of Euro16.05M
- OSE Immunotherapeutics SA press release ( OTC:ORPOF ): 1H GAAP EPS of -€0.11.
- Revenue of €16.05M (+78.7% Y/Y).
- As of June 30, 2022, available cash amounted to €31M, giving a financial visibility until Q3 2023.
For further details see:
OSE Immunotherapeutics SA GAAP EPS of -€0.11, revenue of €16.05M